Table 2.
PDL-L1 expression in immunohistochemistry and mutations found in NGS for the 15 patients.
| Patient | PD-L1 (%) | Predominant mutation | Other mutations |
|---|---|---|---|
| 1 | 0 | TP53 p.Pro190Arg c.569C>G | — |
| 2 | N.A. | NOTCH1c.5019-35C>T | — |
| 3 | 0 | NOTCH1 p.His1591Gln c.4773C>G | — |
| 4 | 0 | FBXW7 p.Val445Val c.1335G>A | TP53 p.Val173Met c.517G>A |
| 5 | 30 | TP53 p.Lys101* c.301A>T | TP53 (NM_000546.5) p.Gly245Val c.734G>T |
| FGFR2 (NM_022970.3) / c.939+43C>T | |||
| 6 | 0 | KRAS p.Gly12Val c.35G>T | — |
| 7 | 30 | KRAS p.Gly12Cys c.34G>T | TP53 (NM_000546.5) p.Arg175His c.524G>A |
| PIK3CA (NM_006218.3) p.Glu545Gly c.1634A>G | |||
| 8 | 0 | TP53 p.Arg337Leu c.1010G>T | — |
| 9 | 0 | SMAD4 p.Gly467Arg c.1399G>A | — |
| 10 | 80 | KDR p.Gln472His c.1416A>T | — |
| 11 | 50 | DDR2c.1505-14G>A | — |
| 12 | 20 | BRAF p.Asn581Ser c.1742A>G | — |
| 13 | 5 | PTEN p.Arg233* c.697C>T | CTNNB1 (NM_001904.3) p.Ser37Phe c.110C>T |
| 14 | 0 | TP53 p.Ser269_Phe270del c.806_808delGCT | — |
| 15 | 20 | PTEN p.Arg233* c.697C>T | CTNNB1 (NM_001904.3) p.Ser37Phe c.110C>T |
| SMAD4 (NM_005359.5) p.Trp398* c.1193G>A |
Predominant mutation was chosen according to the concentration of each mutated allele, based on the allelic frequency and circulating DNA concentrations. PD-L1 expression was evaluated by immunohistochemistry on tumor cells. N.A.: non available.